Open AccessDiabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients
Author(s) -
Serena Tharakan,
Brittney S. Zimmerman,
Meng Ru,
Julia Blanter,
Krystal Pauline Cascetta,
Amy Tiersten
Publication year - 2020
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000506076
Subject(s) - medicine , breast cancer , metformin , diabetes mellitus , oncology , cohort , cancer , stage (stratigraphy) , comorbidity , gynecology , endocrinology , insulin , paleontology , biology
The Oncotype DX® (ODX) is a genomic assay that provides clinicians with a prediction of benefit of chemotherapy in node-negative, tamoxifen-treated breast cancer. However, the relationship between ODX recurrence score (RS) and diabetes, a common comorbidity in breast cancer patients, has been inadequately described in the literature. Specifically, the association of diabetes treatment with metformin and RS is inconclusive, with different studies reporting conflicting results. Because diabetes has been associated with higher RS, it has been suggested that management of diabetes with metformin in breast cancer patients may be associated with a lower RS.